First Republic Investment Management Inc. bought a new position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,394 shares of the company’s stock, valued at approximately $201,000.
Several other institutional investors have also added to or reduced their stakes in PCRX. Mizuho Securities USA LLC raised its stake in shares of Pacira Pharmaceuticals by 20.8% in the fourth quarter. Mizuho Securities USA LLC now owns 9,300 shares of the company’s stock worth $425,000 after acquiring an additional 1,600 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Pacira Pharmaceuticals by 1.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 152,857 shares of the company’s stock worth $6,978,000 after buying an additional 1,779 shares during the last quarter. Dupont Capital Management Corp raised its stake in shares of Pacira Pharmaceuticals by 13.7% during the third quarter. Dupont Capital Management Corp now owns 15,090 shares of the company’s stock worth $567,000 after buying an additional 1,821 shares during the last quarter. American International Group Inc. grew its holdings in Pacira Pharmaceuticals by 8.1% during the third quarter. American International Group Inc. now owns 26,346 shares of the company’s stock valued at $989,000 after purchasing an additional 1,970 shares during the period. Finally, Hodges Capital Management Inc. grew its holdings in Pacira Pharmaceuticals by 40.0% during the third quarter. Hodges Capital Management Inc. now owns 7,000 shares of the company’s stock valued at $263,000 after purchasing an additional 2,000 shares during the period.
In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 6.60% of the company’s stock.
Pacira Pharmaceuticals Inc (PCRX) opened at $30.90 on Friday. The company has a quick ratio of 6.22, a current ratio of 6.96 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1,227.46, a PE ratio of -28.35 and a beta of 1.95. Pacira Pharmaceuticals Inc has a fifty-two week low of $29.35 and a fifty-two week high of $52.47.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The business had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. During the same period in the previous year, the business posted $0.09 EPS. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. analysts predict that Pacira Pharmaceuticals Inc will post -0.58 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on the stock. Mizuho cut shares of Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $53.00 to $44.00 in a report on Wednesday, November 29th. JPMorgan Chase & Co. restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th. HC Wainwright set a $55.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, January 4th. Canaccord Genuity set a $46.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, January 4th. Finally, Royal Bank of Canada set a $54.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, January 4th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $45.29.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/18/first-republic-investment-management-inc-buys-new-holdings-in-pacira-pharmaceuticals-inc-pcrx.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.